ASX CODE

AXI

ISSUED CAPITAL

Ordinary Shares 442.2 M

CONTACT

South Australia

Level 3, Stafford House 25 Leigh Street Adelaide SA 5000

Phone: (08) 8120 2400 Email: paul@axiompl.com.au

New South Wales

Suite 2001, Lvl 20 Australia Square 264-278 George Street Sydney NSW 2000

Phone: (02) 8243 2800 Fax: (02) 9251 1838 Email: ben@axiompl.com.au



23 December 2013

ASX RELEASE

APPENDIX 3B


Adelaide, Australia, Monday 23 December 2013: Axiom Properties Limited (ASX:AXI) lodges the attached Appendix 3B New issue announcement, application for quotation of additional securities and agreement.

This Appendix 3B is to be read in conjunction with the Appendix 3B ASX release made on 18 November 2013 with headline Employee Performance Rights Plan. As advised in the previous release, the performance hurdles for tranche 1 were already met as at date of issue and have now vested. The attached Appendix 3B confirms the vesting of tranche 1 of 1,500,000 shares to employees and the resulting change to total number of ordinary shares.

About Axiom Properties Ltd

Axiom Properties Ltd is a property development and investment business focused on developing and delivering quality property solutions. Axiom's principal objective is to create long term value for shareholders through creating a well-respected property development and investment company that consistently delivers above industry returns on capital.

For more information, please contact: Paul Santinon Company Secretary +61 8 8120 2400



Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

ABN 40 000	9 063 834		
We (t	We (the entity) give ASX the following information.		
	1 - All issues ust complete the relevant sections (attac	h sheets if there is not enough space).	
1	⁺ Class of ⁺ securities issued or to be issued	Ordinary Fully Paid Shares	
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,500,000	
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Ordinary Fully Paid Shares	
	to be issued (if known) or maximum number which may be issued Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for		

Name of entity

Axiom Properties Limited

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Yes
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	\$nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	The ordinary fully paid shares are issued following exercise of vested Performance Rights in accordance with Axiom Properties Limited's Performance Rights Plan.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	
6c	Number of *securities issued without security holder approval under rule 7.1	

Appendix 3B Page 2 01/08/2012

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A		
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)		
6f	Number of securities issued under an exception in rule 7.2		
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.		
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements		
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	29 November 2013	
		Number	⁺ Class
8	Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)	442,240,643	Ordinary Fully Paid Shares

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and +class of all +securities not quoted on ASX (<i>including</i> the securities in section 2 if applicable)	Nil	
	D: : 1 1 1: /: .1 C		
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	The abovementioned with existing ordinary	shares rank pari passu fully paid shares.
Part	2 - Bonus issue or pro ra	nta issue	
11	Is security holder approval required?		
12	Is the issue renounceable or non-renounceable?		
13	Ratio in which the *securities will be offered		
14	⁺ Class of ⁺ securities to which the offer relates		
15	⁺ Record date to determine entitlements		
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?		
17	Policy for deciding entitlements in relation to fractions		
18	Names of countries in which the		
10	entity has *security holders who will not be sent new issue documents		
	Note: Security holders must be told how their entitlements are to be dealt with.		
	Cross reference: rule 7.7.		

Appendix 3B Page 4 01/08/2012

⁺ See chapter 19 for defined terms.

19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders
25	If the issue is contingent on +security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do *security holders sell their entitlements in full through a broker?
31	How do +security holders sell

⁺ See chapter 19 for defined terms.

	the balanc			
32	of their e	ecurity holders dispose ntitlements (except by gh a broker)?		
33	⁺ Despatch	date		
Part	3 - Quot	ation of securitie	S	
You nee	ed only compl	ete this section if you are ap	plying for quotation of securities	
34	Type of sec (tick one)	curities		
(a)	Secu	urities described in Part		
(b)	All	other securities		
	emple	Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entitio	es that hav	ve ticked box 34(a)		
Addit	ional secu	urities forming a new	class of securities	
Tick to docume		are providing the informat	ion or	
35	└── add		securities, the names of the 20 largest holders of the he number and percentage of additional *securities	
36	+sec 1 - 1, 1,00 5,00 10,0	curities setting out the nu	securities, a distribution schedule of the additional amber of holders in the categories	
37			the additional ⁺ securities	

Appendix 3B Page 6 01/08/2012

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)			
38	Number of securities for which ⁺ quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)		
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 †securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 23 December 2013

Company Secretary

Print name: Paul Santinon

== == == ==

Appendix 3B Page 8 01/08/2012

⁺ See chapter 19 for defined terms.

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue		
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2		
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ordinary securities that became fully paid in that 12 month period		
Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items Subtract the number of fully paid ordinary securities cancelled during that 12 month.		
securities cancelled during that 12 month period		
"A"		

Appendix 3B Page 10 01/08/2012

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15		
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"		
Step 4: Subtract "C" from ["A" x "Eplacement capacity under rule 7.1 "A" x 0.15 Note: number must be same as shown in	3"] to calculate remaining	
Step 2		
Subtract "C"		
Note: number must be same as shown in Step 3		
Total ["A" x 0.15] – "C"		
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
0.10		
Note: this value cannot be changed		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		

Appendix 3B Page 12 01/08/2012

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A			
"A" x 0.10			
Note: number must be same as shown in Step 2			
Subtract "E"			
Note: number must be same as shown in Step 3			
Total ["A" x 0.10] – "E"			
	Note: this is the remaining placement capacity under rule 7.1A		

⁺ See chapter 19 for defined terms.